The Journal of asthma : official journal of the Association for the Care of Asthma · 2026
Effectiveness of short-acting beta-2 agonists delivered by metered-dose inhaler with spacer versus nebulizer in acute asthma exacerbations: a systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adadja Judicael, Boumenna Tarek, Bergeron Frederic, Daigneault Patrick, Guertin Jason R, Berthelot Simon
Аннотация
OBJECTIVE: This systematic review and meta-analysis aimed to compare the clinical effectiveness of short-acting β2-agonist (SABA) delivery via metered-dose inhaler with spacer versus nebulizer in patients with acute asthma exacerbations.
METHODS: A comprehensive search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 14, 2025. Randomized controlled trials (RCTs) involving patients aged 2 years or older comparing SABA administration via metered-dose inhaler with spacer versus nebulizer were included. The primary outcome was hospital admission; secondary outcomes included length of stay, return visit within 72 h, peak expiratory flow, forced expiratory volume in one second, oxygen saturation, respiratory rate, heart rate, and tremor. Two reviewers independently selected studies, extracted data, and assessed risk of bias using the RoB 2 tool. Random-effects meta-analyses were conducted, with separate analyses for pediatric and adult populations. The certainty of evidence was assessed using the GRADE approach. The protocol was registered in PROSPERO (CRD42023445698).
RESULTS: Twenty RCTs (2235 participants) were included. No significant difference in hospital admission was observed overall (RR = 0.90; 95% CI [0.69 to 1.18]; I2 = 0%), nor in adults, children, or severe exacerbations. Secondary outcomes showed no significant differences overall. In children, however, MDI with spacer was associated with shorter ED stays and a lower risk of tremor. Certainty of evidence ranged from moderate to very low.
CONCLUSION: SABA delivery via MDI with spacer showed comparable clinical outcomes to nebulization for acute asthma exacerbations, with potential pediatric advantages in reducing ED length of stay and the risk of tremor.
METHODS: A comprehensive search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 14, 2025. Randomized controlled trials (RCTs) involving patients aged 2 years or older comparing SABA administration via metered-dose inhaler with spacer versus nebulizer were included. The primary outcome was hospital admission; secondary outcomes included length of stay, return visit within 72 h, peak expiratory flow, forced expiratory volume in one second, oxygen saturation, respiratory rate, heart rate, and tremor. Two reviewers independently selected studies, extracted data, and assessed risk of bias using the RoB 2 tool. Random-effects meta-analyses were conducted, with separate analyses for pediatric and adult populations. The certainty of evidence was assessed using the GRADE approach. The protocol was registered in PROSPERO (CRD42023445698).
RESULTS: Twenty RCTs (2235 participants) were included. No significant difference in hospital admission was observed overall (RR = 0.90; 95% CI [0.69 to 1.18]; I2 = 0%), nor in adults, children, or severe exacerbations. Secondary outcomes showed no significant differences overall. In children, however, MDI with spacer was associated with shorter ED stays and a lower risk of tremor. Certainty of evidence ranged from moderate to very low.
CONCLUSION: SABA delivery via MDI with spacer showed comparable clinical outcomes to nebulization for acute asthma exacerbations, with potential pediatric advantages in reducing ED length of stay and the risk of tremor.